Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

John A. Borgeson net worth and biography

John Borgeson Biography and Net Worth

Insider of Kodiak Sciences

John Borgeson is our Senior Vice President and Chief Financial Officer and has served in this position since January 2016. From January 2013 until December 2015, Mr. Borgeson led finance for a variety of private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals. Previously, Mr. Borgeson was a Vice President of Finance at Pfizer Inc. and a member of Pfizer’s Global Finance and Business Operations Leadership Team. Mr. Borgeson’s roles at Pfizer included finance head for Pfizer’s biotherapeutics and bioinnovation group and corporate tax executive with responsibility for the United States and Europe. Under Mr. Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Mr. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant (inactive). He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.)

How old is John A. Borgeson?: Mr. Borgeson is currently 62 years old. There are 2 older executives and no younger executives at Kodiak Sciences. Learn More on John A. Borgeson's age.
How do I contact John A. Borgeson?: The corporate mailing address for Mr. Borgeson and other Kodiak Sciences executives is 2631 HANOVER STREET, PALO ALTO CA, 94304. Kodiak Sciences can also be reached via phone at (650) 281-0850 and via email at [email protected]. Learn More on John A. Borgeson's contact information.
Has John A. Borgeson been buying or selling shares of Kodiak Sciences?: John A. Borgeson has not been actively trading shares of Kodiak Sciences during the last ninety days. Most recently, John A. Borgeson sold 876 shares of the business's stock in a transaction on Wednesday, November 10th. The shares were sold at an average price of $115.42, for a transaction totalling $101,107.92. Learn More on John A. Borgeson's trading history.
Who are Kodiak Sciences' active insiders?: Kodiak Sciences' insider roster includes John Borgeson (Insider), and Jason Ehrlich (Insider). Learn More on Kodiak Sciences' active insiders.
Are insiders buying or selling shares of Kodiak Sciences?: In the last year, insiders at the sold shares 2 times. They sold a total of 3,390 shares worth more than $31,504.78. The most recent insider tranaction occured on June, 16th when insider Jason Ehrlich sold 2,258 shares worth more than $20,841.34. Insiders at Kodiak Sciences own 45.4% of the company. Learn More about insider trades at Kodiak Sciences.
Information on this page was last updated on 6/16/2023.

John A. Borgeson Insider Trading History at Kodiak Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/10/2021	Sell	876	$115.42	$101,107.92

John A. Borgeson Buying and Selling Activity at Kodiak Sciences

Kodiak Sciences Company Overview

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Today's Range

Now: $3.51

$3.34

$3.56

50 Day Range

MA: $5.24

$3.36

$7.45

2 Week Range

Now: $3.51

$1.37

$9.80

Volume

76,171 shs

Average Volume

834,666 shs

Market Capitalization

$184.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad